Cargando…
Pathological MAPK activation–mediated lymphatic basement membrane disruption causes lymphangiectasia that is treatable with ravoxertinib
Lymphangiectasia, an anomalous dilation of lymphatic vessels first described in the 17th century, is frequently associated with chylous effusion, respiratory failure, and high mortality in young patients, yet the underlying molecular pathogenesis and effective treatments remain elusive. Here, we ide...
Autores principales: | Janardhan, Harish P., Dresser, Karen, Hutchinson, Lloyd, Trivedi, Chinmay M. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
American Society for Clinical Investigation
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9536262/ https://www.ncbi.nlm.nih.gov/pubmed/36073544 http://dx.doi.org/10.1172/jci.insight.153033 |
Ejemplares similares
-
KRAS or BRAF mutations cause hepatic vascular cavernomas treatable with MAP2K–MAPK1 inhibition
por: Janardhan, Harish Palleti, et al.
Publicado: (2020) -
Sustained Activation of Endothelial YAP1 Causes Epithelioid Hemangioendothelioma
por: Jung, Roy, et al.
Publicado: (2021) -
Therapeutic Lymphatic Embolization in Pediatric Primary Intestinal Lymphangiectasia
por: Kwon, Yiyoung, et al.
Publicado: (2021) -
Hdac3 regulates lymphovenous and lymphatic valve formation
por: Janardhan, Harish P., et al.
Publicado: (2017) -
Refractory lymphatic ascites following laparoscopic management of renal lymphangiectasia: An unusual presentation
por: Saini, Sumit, et al.
Publicado: (2021)